⚠ Disclaimer: This report is generated using AI tools and is for informational purposes only. It does not constitute investment advice. Please consult a registered financial advisor before making any investment decisions.

NEWGEN - Fundamental Analysis: Financial Health & Valuation

← Back to List

⭐ Rating: 4

Last Updated Time : 02 Aug 26, 06:36 pm

Key Parameters

⭐ Fundamental Rating: 4.0

Stock CodeNEWGEN
Market Cap7,909 Cr.
Current Price556 ₹
High / Low1,042 ₹
Stock P/E24.3
Book Value115 ₹
Dividend Yield1.08 %
ROCE25.4 %
ROE20.2 %
Face Value10.0 ₹
DMA 50508 ₹
DMA 200615 ₹
Chg in FII Hold-0.70 %
Chg in DII Hold-0.70 %
PAT Qtr59.8 Cr.
PAT Prev Qtr110 Cr.
RSI60.1
MACD14.7
Volume13,38,449
Avg Vol 1Wk46,58,286
Low price401 ₹
High price1,042 ₹
PEG Ratio1.07
Debt to equity0.02
52w Index24.1 %
Qtr Profit Var22.8 %
EPS20.8 ₹
Industry PE23.0

✅ Positive

Newgen Software Technologies has demonstrated robust revenue growth, particularly evident in the recent quarter with a significant PAT increase. The company maintains strong profitability metrics like a high ROCE of 25.4% and a solid debt-to-equity ratio of 0.02, indicating financial health.

⚠️ Limitation

Despite impressive short-term gains, the stock’s valuation is relatively high based on its P/E ratio of 24.3, potentially limiting upside potential. The company's reliance on specific IT services and emerging market competition pose ongoing risks to sustained growth.

📉 Company Negative News

Recent news indicates a significant one-month return for the stock and a substantial daily gain fueled by analyst optimism. However, this surge may be driven by short-term momentum rather than underlying fundamentals, which could lead to a correction.

📈 Company Positive News

None found

🏭 Industry

The IT services sector is currently experiencing strong demand due to digitalization trends and cloud computing adoption, presenting opportunities for growth-oriented companies. However, the industry faces intense competition, regulatory scrutiny, and cyclical fluctuations in demand.

🧾 Conclusion

We recommend an entry zone between 520 ₹ - 540 ₹, capitalizing on what appears to be a temporary overreaction and recognizing underlying strength. A long-term holding strategy is advised, aiming for growth driven by continued expansion in healthcare and financial services, with periodic reevaluation of the company's strategic direction and competitive positioning – maintaining a target horizon of 3-5 years. The stock presents a reasonable investment opportunity despite the elevated valuation.

Technical Analysis
Fundamental Analysis

NIFTY 50 · Fundamental

NEXT 50 · Fundamental

MIDCAP · Fundamental

SMALLCAP · Fundamental